ArticleProgress in molecular biology and translational science2011
Cell delivery of therapeutic nanoparticles.
Article in Progress in molecular biology and translational science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Trial
- Development of ascorbyl palmitate based hydrophobic gold nanoparticles as a nanocarrier system for gemcitabine delivery.Scientific reports · 2025Article
- Advanced nanotherapies for precision treatment of inflammatory lung diseases.Bioactive materials · 2025Review
- Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations.Current treatment options in oncology · 2025Review
- Biobased Nanomaterials: Pioneering Innovations for Biomedical Advancements.Pharmaceutical nanotechnology · 2025Review
- Preparation and characterization of immobilized indole-3-butyric acid on silver-cerium oxide nanoparticles for improving its stability and utilization in the study of plant root formation indices.Frontiers in plant science · 2025Article
- Nanotechnology in retinal diseases: From disease diagnosis to therapeutic applications.Biophysics reviews · 2024Review
- Formulation of Polymeric Nanoparticles Loading Baricitinib as a Topical Approach in Ocular Application.Pharmaceutics · 2024Article
- Review
- Elucidation of Protonation Cooperativity of a STING-Activating Polymer.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Therapeutic Applications of Mesenchymal Stem Cell Loaded with Gold Nanoparticles for Regenerative Medicine.Pharmaceutics · 2023Article
- Controlled Release of DNA Binding Anticancer Drugs from Gold Nanoparticles with Near-Infrared Radiation.Journal of pharmaceutical sciences · 2023Article
- Safety and Toxicity Implications of Multifunctional Drug Delivery Nanocarriers on Reproductive SystemsFrontiers in toxicology · 2022Review
- The In Vitro Immunomodulatory Effects of Gold Nanocomplex on THP-1-Derived Macrophages.Journal of immunology research · 2022Article
- Nano Drug Delivery Platforms for Dental Application: Infection Control and TMJ Management-A Review.Polymers · 2021Article
- DNA Dendrons as Agents for Intracellular Delivery.Journal of the American Chemical Society · 2021Article
- Alginate Nanoparticles Enhance Anti-Clostridium perfringens Activity of the Leaderless Two-Peptide Enterocin DD14 and Affect Expression of Some Virulence Factors.Probiotics and antimicrobial proteins · 2021Article
- Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy.Cell & bioscience · 2021Review
- Recent Developments in Nanomaterial-Based Shear-Sensitive Drug Delivery Systems.Advanced healthcare materials · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that are packaged into nanoscale systems for improved delivery. This includes known drugs, proteins, enzymes, and antibodies that have limited clinical efficacy based on delivery, circulating half-lives, or toxicity profiles. The <100 nm nanoscale physical properties afford them a unique biologic potential for biomedical applications. Hence they are attractive systems for treatment of cancer, heart and lung, blood, inflammatory, and infectious diseases. Proposed clinical applications include tissue regeneration, cochlear and retinal implants, cartilage and joint repair, skin regeneration, antimicrobial therapy, correction of metabolic disorders, and targeted drug delivery to diseased sites including the central nervous system. The potential for cell and immune side effects has necessitated new methods for determining formulation toxicities. To realize the potential of nanomedicine from the bench to the patient bedside, our laboratories have embarked on developing cell-based carriage of drug nanoparticles to improve clinical outcomes in infectious and degenerative diseases. The past half decade has seen the development and use of cells of mononuclear phagocyte lineage, including dendritic cells, monocytes, and macrophages, as Trojan horses for carriage of anti-inflammatory and anti-infective medicines. The promise of this new technology and the perils in translating it for clinical use are developed and discussed in this chapter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.